Early Look

Monday, November 16, 2026

Futures

Up/Down

%

Last

Dow

43.00

0.08%

52,461

S&P 500

-23.25

0.31%

7,559

Nasdaq

-240.50

0.86%

27,794

 

 

U.S. futures are looking lower, especially added weakness in the technology sector after fallout from the NVDA CEO departure last week raises concerns about further AI spending. The Federal Reserve also released their financial stability report immediately after the market close on Friday. The Fed said it sees risks on elevated asset prices partly driven by Ai. Ai Computing investment has been accelerating, suggesting pace of current cycle’s investment may soon surpass 1990s telecom Cycle. The report said 87% of survey respondents cited Ai as a salient risk to financial stability. Still, all eleven S&P sectors finished higher last week despite selling off Thursday/Friday, led by Energy (XLE +5.37% WTD), Communications (XLC +3.72%), Industrials (XLI +3.73%), and Technology (XLK +3.3%) as the S&P 500 gained 2.51%, the Nasdaq climbed 2.27%, and the Dow climbed 2.07%. The S&P 500 and Nasdaq both snapped four-week losing streaks. Tech trade remains in focus amid reports that supporters of Jensen Huang are lobbying for his return to the AI chip giant following his abrupt resignation last week. Also, a make of break moment for AI trade as the Anthropic (ANT) IPO is expected to price this week.

 

In Asian markets, The Nikkei Index tumbled 1,480 points to 59,662, the Shanghai Index fell -31 points to 3,602, the Kospi fell -4% or 33 points to 791 and the Hang Seng Index rose 116 points to 23,753. In Europe, the German DAX is down -32 points to 26,716, while the FTSE 100 rises 26 points to 10,928. In US economic data, Monday brings us the November Empire State manufacturing survey. Fed speakers include Fed Governor Barr, New York Fed President Williams and Fed Chair Warsh. Bitcoin -0.5% after falling more this weekend, trading to $64,670 as crypto assets continue to fall given a rise in the dollar and US Treasury yields in rising inflation and interest rate hike fears.

 

Anthropic is expected to price its initial public offering (IPO) on Wednesday, Nov. 18. It will begin trading under the ticker symbol "ANT" on Thursday, Nov. 19. In an amended S-1 filing released Tuesday, Anthropic said it expects to sell 825 million shares priced between $70 and $78. That would give the company a market valuation of between $1.3 trillion and $1.45 trillion. Anthropic was initially projected to hit the market with a valuation as high as $2 trillion, but recent market turmoil in the AI sector has knocked that down significantly. For the first nine months of the year ending Sept. 30, Anthropic said revenue grew $1,206% to $33.2 billion.

 

Market Closing Prices Yesterday

  • The S&P 500 Index dropped -30.73 points, or 0.40%, to 7,561.67
  • The Dow Jones Industrial Average rose 50.46 points, or 0.10%, to 52,347.55
  • The Nasdaq Composite tumbled -229.82 points, or 0.91%, to 25,136.27
  • The Russell 2000 Index declined -8.57 points, or 0.31% to 2,790.49

Economic Calendar for Today

  • 8:30 AM ET NY Empire Manufacturing for November

Earnings Calendar:

  • Earnings Before the Open: ARMK BEKE BIDU BLDP BXDC DTST GAME HTHT IQ PERI POET TSN VENU XPEV XTNT XXII
  • Earnings After the Close: ACM AYTU BAER BRFH DARE DUOT FTLF INFQ MNTK OMER PAGS PARA POWL RCAT SHAZ STEM TMS TRAK WRAP XP YALA

Other Key Events:

  • Piper Sandler Financial Services Conference, 11/16-11/18, in Miami, FL
  • RBC Capital Markets Global Industrials Conference 11/16-11/17, in New York
  • Roth Capital 13th Annual Solar & Storage Symposium at RE +, 11/16-11/18, Las Vegas
  • Supercomputing 2026, 11/15-11/20, in New Orleans

 

 

Macro

Up/Down

Last

Nymex

-0.39

88.17

Brent

-0.63

95.21

Gold

-10.90

3,875.40

EUR/USD

-0.0017

1.1004

JPY/USD

-0.05

159.63

10-Year Note

-0.01

5.14%

 

World News

  • US President Trump will hold a trilateral summit with Chinese President Xi and Russian President Putin on the sidelines of the annual APEC conference in Shenzhen on Thursday, the New York Post reported. The trilateral discussion is expected to focus largely on developing an ambitious nuclear arms control pact, but discussions could also touch on North Korea and the Iran war, the Post reported.

Sector News Breakdown

Consumer

  • Aramark (ARMK) Q4 adjusted EPS $0.71 vs. est. $0.75 and revs $5.29B, in-line with consensus $5.29B; sees FY27 adjusted EPS growth 20%-25% vs. $2.23 in FY26; sees FY27 revenue growth 9%-10% vs. $20.09B in FY26; authorizes a $1B share buyback plan and raises dividend by 17%.
  • Xpeng (XPEV) Q3 revenue rose 19% y/y to Q3 revenue RMB 24.28B, consensus RMB 23.17B, driven by higher deliveries and improved product mix; its Q3 net loss widened y/y, while gross margin declined to 18.9%; forecasts Q4 deliveries to rise more than 40% y/y to between 169,000 and 174,000 after Q3 deliveries were 118,390; sees Q4 revenue between RMB30.40B and RMB31.80B.
  • Chinese regulators will conduct annual assessments of 17 major Chinese automakers' payments to suppliers, statements released by the country's industry ministry and the China Association of Automobile Manufacturers showed on Monday.

Energy, Industrials and Materials

  • A Vulcan rocket owned by United Launch Alliance, the joint venture of Boeing (BA) and Lockheed Martin (LMT), failed on Sunday shortly after liftoff from Florida, destroying its payload of 40 satellites from Amazon's Leo internet network in the launch company's first mission failure. The rocket failed ‌roughly 10 minutes after liftoff from the Cape Canaveral Space Force Station in Florida, and the cause was not immediately clear.
  • Canadian Natural Resources (CNQ) will acquire smaller peer Advantage Energy (AAVVF) in a deal valued at C$2.53B ($1.77B), including debt, as Advantage shareholders will receive C$13.55 in cash for each share held, implying a premium of nearly 25% its closing price on Friday. The deal includes production of roughly 79,000 barrels of oil equivalent per day from Montney and Charlie Lake assets, and a light crude oil and liquids‌-‌rich natural gas development inventory adjacent to existing operations in the Grande Prairie area of Alberta.
  • Clearwater Paper Corporation (CLW) announced new leadership appointments; announces Q3 price increase: $50/ton cup, $60/ton folding carton; reaffirms Q4 2026 guidance of $10M-$20M adj ebitda; says Cypress Bend mill outage completed; mill resuming normal operations; expects 2027 capital expenditures within $70 mln-$80 mln maintenance plus $10 mln-$20 mln for projects
  • Diamondback Energy (FANG) is nearing a roughly $5 billion deal to acquire a drilling portfolio from energy producer Double Eagle, expanding its footprint in the oil-rich Permian Basin in Texas, the Financial Times reported, citing people familiar with the matter.
  • Unusual Machines (UMAC) announces secondary offering of 1.9M shares of common stock by selling stockholders.

Healthcare

  • Cytokinetics, Incorporated (CYTK) said the FDA has approved a supplemental New Drug Application (sNDA) updating the U.S. Prescribing Information for MYQORZO(R) (aficamten) to include data from MAPLE-HCM, the Phase 3 trial comparing MYQORZO and the standard-of-care beta-blocker metoprolol, each as monotherapy, in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
  • Henry Schein (HSIC) reduces FY2026 non-Gaap diluted eps guidance to $5.42-$5.48 from $5.50-$5.56 vs. consensus of $5.54 and sees FY sales growth outlook 4.5-5.5%; guidance is for current continuing operations and does not include impact of restructuring expenses.
  • Incyte (INCY) said it has decided not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, the company's selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenance therapy in patients with ovarian cancer, which had been expected to begin in Q4.
  • Johnson & Johnson (JNJ) could announce a deal to buy privately held biotech Ollin Biosciences for up to $3.4B, the Financial Times said, citing people familiar with the matter. Under the terms being discussed, J&J could pay Ollin's backers $2.2B in cash upfront ‌and a further $1.2B in potential milestone payments
  • Summit Therapeutics (SMMT) shares fall after saying the FDA declined approval of their lung cancer drug ivonescimab saying the drug's benefit in delaying disease progression does not support a favorable benefit-risk profile without a statistically significant improvement in overall survival. Ivonescimab plus chemotherapy cut the risk of disease progression or death by 48% versus chemotherapy alone in a late-stage trial, with benefits consistent across Asian and Western patients.
  • Zymeworks (ZYME) announced that its Board of Directors has authorized a second 2026 share repurchase program under which the company may repurchase up to $200M of its outstanding common stock.

Technology, Media & Telecom

  • Nvidia (NVDA) stock futures fell almost 2% on Monday as investors digested a report that supporters of Jensen Huang are lobbying for his return to the AI chip giant following his abrupt resignation last week. Huang has discussed returning as CEO with confidants, the Financial Times reported Sunday, citing people familiar with the matter. Huang resigned last week following reports of affairs, including one with a woman who was reportedly suspected of being a Chinese spy.
  • Server makers' shares continue to slide this morning, with shares of Dell (DELL), Super Micro (SMCI), Hewlett Packard (HPE) adding to last week’s losses following a leadership crisis at AI chip giant Nvidia (NVDA) has exacerbated AI worries amid concerns over spending. DELL has dropped over 40% from Sept peak, HPE down ~34% from Oct record high, SMCI has slumped 75%+ from March 2024 peak.
  • American Tower Corp. (AMT) files for offering of two-part Euro-denominated Senior notes, size not disclosed.
  • Baidu's (BIDU) Q3 revenue slips 1% to RMB 30.8B vs. consensus RMB 30.63B; Q3 Adjusted earnings per ADS for Q3 was RMB6.78, adjusted EBITDA margin was 15%; Q3 AI Cloud Infra revenue grew 94% y/y, offsetting weakness in online marketing. AI-native marketing services revenue fell 15% y/y due to macroeconomic challenges, competition, and prioritizing user experience over near-term monetization

Mid-Morning Look

Monday, November 16, 2026

Index

Up/Down

%

Last

DJ Industrials

-295.16

0.56%

52,052

S&P 500

-91.86

1.21%

7,469

Nasdaq

-504.93

2.01%

24,631

Russell 2000

-28.69

1.03%

2,761

 

 

After a brief bounce last week for major averages (all eleven S&P sectors finished last week higher after a 4 week losing streak previously for the S&P and Nasdaq), stocks are pushing lower again led by a sharp decline in technology stocks (QQQ, SOX, XLK) ahead of two major catalysts this week with NVDA earnings tomorrow night and the Anthropic (ANT) IPO coming this week as well. Oil continues to pull back as Middle East exports look to recover.  Bond yields pull back as investors await comments from Fed Chairman Walsh.

 

Technology stocks are adding to last Thursday/Friday sharp declines, under pressure ahead of Nvidia (NVDA) earnings Tuesday night and Anthropic’s (ANT) highly anticipated IPO later this week. Nvidia shares fall further amid leadership uncertainty after CEO Jensen Huang resigned last week following reports of affairs, including one with a woman who was reportedly suspected of being a Chinese spy and another internal company individual. There were also media reports this weekend that supporters of Jensen Huang are lobbying for his return to the AI chip giant following his abrupt resignation last week. In addition to leadership uncertainty, elevated financing costs and competition for institutional AI allocations are the immediate catalysts for sector weakness. December Fed-rate-hike expectations are firmly established after last week’s inflation data. Among sectors tumbling with NVDA include broad semiconductor pressure linked to AI spending concerns (AMD, AVGO, MU, SNDK), Cloud-computing / financing sensitivity (CRWV, NBIS), AI data-center infrastructure weakness (IREN, HUT, APLD, WULF), Server makers sold with semiconductor complex (DELL, HPE, SMCI). Other concerns include this week’s Anthropic (ANT) IPO listing possibly drawing allocations away from existing AI positions.

 

Treasury yields trade slightly below Friday levels as markets wait for Chairman Warsh's speech at the Fed's Productivity and Jobs Task Force Conference at 12 p.m. ET. The Empire State Manufacturing Survey comes in at a lower-than-expected 7.8, falling from 25.5 in October. Meanwhile, Brent crude slips 2% and the dollar is stable, with the DXY gauge trading above 103.50. The 10-year yield slips to 5.139% from 5.152%, and the two-year declines to 4.844% from 4.872%. Bitcoin fell to its lowest levels since August over the weekend (below $62K) as a wave of forced liquidations accelerated amid broader weakening in market liquidity and risk appetite. and is coming off its sixth weekly decline in a row. On Monday morning, it had climbed back to the $64,000 level. Spot gold falls after touching its lowest level since October 2025 at $3,830 earlier in the session. A firm US dollar, trading near its strongest level since April 2025 weighs on precious metals. Spot silver fell 3.1% to $47.22 per ounce, hitting its lowest level since early November 2025 earlier in the session.

 

Economic Data

  • NY Fed's Empire State current business conditions index +7.8 in November (consensus 18.0) vs +25.5 in October; the new orders index +3.0 in November vs +23.2 in October; six-month business conditions index +28.9 in November vs +21.0 in October; NY Fed's Empire State employment index at +18.1 in November vs +10.3 in October; NY Fed's Empire State prices paid index +45.9 in November vs +59.5 in October.

 

 

Macro

Up/Down

Last

WTI Crude

-1.93

86.63

Brent

-2.52

93.32

Gold

-1.20

3,887.50

EUR/USD

-0.0007

1.1019

JPY/USD

-0.21

159.47

10-Year Note

-0.034

5.12%

 

Sector Movers Today

  • Energy E&P sector: FANG said it would buy certain units of Texas-based energy producer Double Eagle in a $5.03B cash-and-stock deal. Under the deal, FANG will pay about $2.15B in cash and 15.56 million shares of Diamondback common stock. The assets include about 176,000 net acres in the core of the Midland Basin, with estimated 2027 oil production of about 35,000 barrels per day. In another deal, CNQ will acquire smaller peer Advantage Energy (AAVVF) in a deal valued at C$2.53B ($1.77B), including debt, as Advantage shareholders will receive C$13.55 in cash for each share held, implying a premium of nearly 25% its closing price on Friday. The deal includes production of roughly 79,000 barrels of oil equivalent per day from Montney and Charlie Lake assets, and a light crude oil and liquids-rich natural gas development inventory.
  • Transport sector: Friday's nationwide ground stop continued to impact airlines operations through the weekend. Using data from FlightAware, UBS calculated that the average cancelation rates across the top 6 US airlines was 32% on Nov 13, 30% on Nov 14, and ~10% on Nov 15 (as of 7pm ET). Delays % averaged 25 30% across each of the past 3 days. JBLU and AAL had the highest cancelation rates while LUV had the lowest cancelations % across the top 6. As of Sun evening, it appears that operations are set to improve meaningfully come Monday with cancel rates moderating to flat to LSD% across the major airlines. Friday's nationwide ground stop lasted for over 4 hours.
  • Defense sector: LHX shares fell after officials blamed a nationwide flight shutdown on the FAA contractor's router installation. Transportation Secretary Sean Duffy said Friday that LHX was conducting routine maintenance to switch telecommunication lines from old copper wire to fiber at least one remote location. Duffy said investigators had not determined whether installer error or faulty equipment caused the disruption, which affected communications at 17 of 22 FAA en route centers. Drone maker USAR shares fell after William Blair downgraded to MP from OP saying recent feedstock shortages add to its list of near-term challenges/ pushing out USA Rare Earth's sales and margin estimates well into 2028.

 

Stock GAINERS

  • CLW +14%; after announced new leadership appointments and a Q3 price increase of $50/ton on cup and $60/ton on folding carton, reaffirmed Q4 2026 adj EBITDA guidance of $10M-$20M, and said the Cypress Bend mill outage is completed with the mill resuming normal operations
  • CGON +6%; shares jumped after positive phase 3 results for cretostimogene in bladder cancer; Phase 3 PIVOT-006 trial evaluated cretostimogene in non-muscle-invasive bladder cancer; treatment reduced the risk of recurrence by 68% versus current therapy in intermediate-risk patients.
  • LXEO +25%; following positive interim trial results for a treatment for a rare genetic heart disease; said interim data from an ongoing Phase I/II clinical trial of LX2020, a treatment for PKP2 arrhythmogenic cardiomyopathy, strengthened its confidence in the drug's potential.
  • TSN +10%; shares rebound after earnings results as Q4 adj EPS $0.61 top consensus of $0.60 on better revs $14.59B vs. consensus $14.1B though forecast a steeper-than-expected annual revenue decline; now sees FY27 revenue down 3.5% to 5.5% against analysts' 1% decline estimate.
  • XPEV +7%; following earnings as Q3 revenue rose 19% y/y to Q3 revenue RMB 24.28B, consensus RMB 23.17B, driven by higher deliveries and improved product mix; its Q3 net loss widened y/y, while gross margin declined to 18.9%; forecasts Q4 deliveries to rise more than 40% y/y to between 169,000 and 174,000.

 

Stock LAGGARDS

  • ACRS -11%; after announcing Top Line Phase 2 results for its anti-TSLP monoclonal antibody bosakitug (ATI-045) in atopic dermatitis, with the ADMIRATION trial failing to achieve its primary endpoint of percent change in EASI score from baseline at Week 24.
  • ARMK -2%; after earnings results miss; Q4 adjusted EPS $0.71 vs. est. $0.75 and revs $5.29B, in-line with consensus $5.29B; sees FY27 adjusted EPS growth 20%-25% vs. $2.23 in FY26; sees FY27 revenue growth 9%-10% vs. $20.09B in FY26; authorizes a $1B share buyback plan and raises dividend by 17%.
  • MSTR -7%; Bitcoin comes into the week with a 6-week losing streak, and extending losses this morning as rising interest rate hike fears after hotter CPI inflation last week dented crypto appetite along with precious metals; Bitcoin falls below $65,000 (COIN, IBIT, HOOD and Bitcoin miners all pressured).
  • MU -7%; another sharp decline in semiconductor trade, with memory names among hardest hit again heading into NVDA earnings and overall AI spending uncertainty taking down the broader AI trade.
  • SMMT -11%; after saying the FDA declined approval of their lung cancer drug ivonescimab saying the drug's benefit in delaying disease progression does not support a favorable benefit-risk profile without a statistically significant improvement in overall survival.
  • USAR -8%; shares fell after William Blair downgraded to MP from OP saying recent feedstock shortages add to its list of near-term challenges/ pushing out USA Rare Earth's sales and margin estimates well into 2028.

Closing Recap

Monday, November 16, 2026

Index

Up/Down

%

Last

DJ Industrials

-737.24

1.41%

51,610

S&P 500

-144.55

1.91%

7,417

Nasdaq

-626.52

2.49%

24,509

Russell 2000

-47.51

1.70%

2,742

 

 

 

 

 

 

 

 

 

U.S. stocks were better for sale most of Monday, with the S&P 500 and Nasdaq falling a third straight day as another concentrated AI themed/semiconductor selloff pulled the Nasdaq below the broader market (and further back below its key 200dma technical support). Investors now await NVDA earnings Tuesday night and face fresh U.S. restrictions on overseas access to advanced AI chips. Defensive sectors in the S&P 500 such as Consumer Staples (XLP) and Healthcare (XLV) both moved back near all-time highs before fading, but held up better than the rest of the S&P 500. Even tumbling oil prices and a slight easing in Treasury yields have not been able to stabilized the tech trade which has been in free fall for a few weeks now, even prior to the NVDA bombshell last week of CEO Jensen Huang stepping down amid reports of extra martial affairs, including one with a woman who was reportedly suspected of being a Chinese spy and another internal company individual.  Overall lots of investor concern heading into Nvidia earnings and Anthropic (ANT) IPO this week as the whole ai complex from semi chips, memory, data centers, opticals, infrastructure, cooling names ave been bleeding for weeks amid uncertainty. While the exodus in tech continues, names in Healthcare (XLV) and Consumer Staples (XLP) making new all-time highs today, among them including KO, LLY, MO and COST. Also this week, the Shenzhen APEC summit (Nov 16-20) is expected to bring a third Trump-Xi meeting of 2026, with the trade truce only temporarily extended. Lots of fear again as the CBOE Volatility index (VIX) jumped as much as 25% above the 24 level as stocks slipped.

 

Lots of weird instances going on the last few days that has a lot of people’s attention. Another tech outage messed with Wall Street and other individuals on Monday after several United States banks and financial institutions were hit, simultaneously, with widespread login issues. JP Morgan customers had reported that they cannot log in to online or mobile banking. Outage reports also surged for Bank of America, U.S. Bank, Wells Fargo, Truist, and Zelle, along with Microsoft 365, Outlook, and Teams. More issues now after the widespread Microsoft (MSFT) outage from late last week that lasted over two days impacting Outlook, Teams and other products, and then the FAA airline ground halt Friday and partial Saturday.

 

Technology stocks added to last Thursday/Friday sharp declines, under pressure ahead of Nvidia (NVDA) earnings Tuesday night and Anthropic’s (ANT) highly anticipated IPO later this week. Nvidia shares fall further amid leadership uncertainty after CEO Jensen Huang resigned last week following reports of affairs, including one with a woman who was reportedly suspected of being a Chinese spy and another internal company individual. There were also media reports this weekend that supporters of Jensen Huang are lobbying for his return to the AI chip giant following his abrupt resignation last week – however, CNBC reported this afternoon Nvidia’s board is not considering bringing Jensen Huang back as CEO. In addition to leadership uncertainty, elevated financing costs and competition for institutional AI allocations are the immediate catalysts for sector weakness. December Fed-rate-hike expectations are firmly established after last week’s inflation data. Among sectors tumbling with NVDA include broad semiconductor pressure linked to AI spending concerns (AMD, AVGO, MU, SNDK), Cloud-computing / financing sensitivity (CRWV, NBIS), AI data-center infrastructure weakness (IREN, HUT, APLD, WULF), Server makers sold with semiconductor complex (DELL, HPE, SMCI). Other concerns include this week’s Anthropic (ANT) IPO listing possibly drawing allocations away from existing AI positions.

Economic Data/Fed speakers

  • NY Fed's Empire State current business conditions index +7.8 in November (consensus 18.0) vs +25.5 in October; the new orders index +3.0 in November vs +23.2 in October; six-month business conditions index +28.9 in November vs +21.0 in October; NY Fed's Empire State employment index at +18.1 in November vs +10.3 in October; NY Fed's Empire State prices paid index +45.9 in November vs +59.5 in October.
  • Federal Reserve Bank of Cleveland President Beth Hammack reiterated that while she sees mounting inflation pressures she is not ready for the US central bank to shift to a more aggressive path of interest rate increases. “I like moving in smaller increments,” Hammack said in a Bloomberg TV interview. “I think the more predictable we can be, the better it is for businesses and households to be able to plan and to think about their finances,” she said.

Commodities

  • Another very broad sell off in the precious metals sector, with gold, silver, palladium and platinum all adding to pullbacks. December gold fell -$33.30 or 0.86% to settle at $3,853 an ounce while December silver prices dropped -$2.26 or 4.6% to end at $46.86 an ounce (a far cry off the $121 an ounce level back in January). Platinum and palladium also fall again, as both have lost more than 11% over the past month. The same pressures dragging gold and silver to one-year lows…a dollar at a 19-month high and bets on more Fed rate hikes. There's a demand worry, too. Platinum and palladium go mainly into catalytic converters for cars, and Monday's figures from China, the world's biggest auto market, showed factory output growing more slowly than expected in October and retail sales cooling.
  • Oil prices fell, giving some relief to recent inflation concerns, following signs of recovering oil flows through the Strait of Hormuz. The International Energy Agency said on Friday that the global oil market will return to a surplus in the fourth quarter of this year. U.S. WTI crude oil futures settle at $85.72 per barrel, down -$2.84, or 3.21% while Brent crude fell -$3.40 or 3.55% to settle at $92.44 per barrel. Prices for both are down about 6% from a week ago as traders lean into forecasts for a growing surplus. Stocks of crude oil in the US strategic Petroleum reserve fell to 276.4M barrels last week, lowest level since 1982.

Currencies & Treasuries

  • The U.S. dollar is the strongest versus the euro since April 2025, despite questions around the AI trade. (Since the end of September, the Nasdaq is down 6+% while the equal weight is up 6+%.) This raises questions of how connected US economic strength is tied to AI equity outperformance. The euro tests below 1.10 to the downside on rising interest rate hike expectations into FOMC meeting minutes due on Wednesday. Dollar index (DXY) tops 103.50 today.
  • US Treasury yields eased slightly on Monday after two-year yields on Friday registered their biggest weekly jump in two years, with a drop in equities giving bonds a slight safe-haven bid. Data last week showed consumer prices rose more quickly than expected in October, prompting markets to factor in more interest rate hikes in coming months. Recent hawkish Federal Reserve official commentary added to the rate hike views. Yields were sharply higher last week as traders saw rising chances that the US central bank could hike rates by a larger-than-usual 50 basis points in December, or raise rates by 25 basis points at each of the next three meetings.

 

Macro

Up/Down

Last

WTI Crude

-2.84

85.72

Brent

-3.40

92.44

Gold

-33.30

3,853.00

EUR/USD

-0.0013

1.1012

JPY/USD

-0.31

159.37

10-Year Note

-0.032

5.121%

 

Sector News Breakdown

Retail, Consumer Staples & Restaurants:

  • Off-price retailers: Truist previews Q3 earnings, saying they remain more bullish on ROST's differentiated approach/momentum. Ahead of Q3 results, Truist thinks key debates for off-price retailers are centered around 1) ROST's ability to sustain momentum into FY27 with increasingly difficult comparisons, 2) if/when Marmaxx can Re-accelerate comps, and 3) the Magnitude of potential weather headwinds (particularly at BURL). While Truist Card Data indicates trends have slowed over the past few weeks, Truist remains bullish on a strong Holiday season overall for off-price (particularly ROST ).
  • Food sector: TSN shares rebound after earnings results as Q4 adj EPS $0.61 top consensus of $0.60 on better revs $14.59B vs. consensus $14.1B though forecast a steeper-than-expected annual revenue decline; now sees FY27 revenue down 3.5% to 5.5% against analysts' 1% decline estimate and forecasts fiscal 2027 adjusted operating income of $1.7 billion to $2.15 billion. Defensive food stocks rallied CPB, GIS, CAG.
  • Specialty retailers: YETI was downgraded to Neutral from Buy at Goldman Sachs as softer U.S. DTC demand, slowing wholesale growth and rising input/freight costs reduce near-term growth and margin visibility.

Autos, Leisure, Gaming & Lodging:

  • Cruise line sector: VIK was double upgraded to Outperform from Underperform at Mizuho and raise PT to $120 from $82 noting shares have lagged materially, underperforming cruise peers (RCL and CCL) over the last 6 months, in large part due to lower River levels in Europe, which Mizuho believes to be transitory. There will be a material impact to '27 and '28; However, once that is digested, believes the focus shifts to '29, where it sees significant upside to numbers.
  • Casinos & Gaming sector: Nine Democratic senators including Adam Schiff (Calif.), Amy Klobuchar (Minn.) and Elissa Slotkin (Mich.) this morning sent a letter to the Commodity Futures Trading Commission (CFTC) asking it to freeze its efforts to assert its regulatory authority over prediction markets. The senators' request comes after the CFTC on Nov. 5 ordered prediction markets to cease geographic restrictions on their platforms within 30 days – WSJ reported.
  • Consumer Services: ARMK Q4 adjusted EPS $0.71 vs. est. $0.75 and revs $5.29B, in-line with consensus $5.29B; sees FY27 adjusted EPS growth 20%-25% vs. $2.23 in FY26; sees FY27 revenue growth 9%-10% vs. $20.09B in FY26; authorizes a $1B share buyback plan and raises dividend by 17%.
  • Auto sector: Chinese Ev maker XPEV Q3 revenue rose 19% y/y to Q3 revenue RMB 24.28B, consensus RMB 23.17B, driven by higher deliveries and improved product mix; its Q3 net loss widened y/y, while gross margin declined to 18.9%; forecasts Q4 deliveries to rise more than 40% y/y to between 169,000 and 174,000 after Q3 deliveries were 118,390; sees Q4 revenue between RMB30.40B and RMB31.80B.

Energy

  • Energy E&P sector: FANG said it would buy certain units of Texas-based energy producer Double Eagle in a $5.03B cash-and-stock deal. Under the deal, FANG will pay about $2.15B in cash and 15.56 million shares of Diamondback common stock. The assets include about 176,000 net acres in the core of the Midland Basin, with estimated 2027 oil production of about 35,000 barrels per day. In another deal, CNQ will acquire smaller peer Advantage Energy (AAVVF) in a deal valued at C$2.53B ($1.77B), including debt, as Advantage shareholders will receive C$13.55 in cash for each share held, implying a premium of nearly 25% its closing price on Friday. The deal includes production of roughly 79,000 barrels of oil equivalent per day from Montney and Charlie Lake assets, and a light crude oil and liquids-rich natural gas development inventory.

Financials

  • Crypto sector: Bitcoin comes into the week with a 6-week losing streak, and extending losses this morning as rising interest rate hike fears after hotter CPI inflation last week dented crypto appetite along with precious metals; Bitcoin falls below $65,000 (COIN, MSTR, IBIT, HOOD and Bitcoin miners all pressured).
  • Brokerage sector (HOOD, SCHW, ETOR, BULL, IBKR): Compass Point says they believe Anthropic (ANT) IPO can make or break 4Q Numbers. October trading activity increased slightly MoM alongside a favorable calendar shift. While October is historically eBrokers' best month of the year, choppy markets limited this year's sequential improvement. Industry commentary suggests November volumes are trending higher MoM. They view ANT's IPO as a barometer for whether retail brokers meet 4Q expectations.

Biotech & Pharma:

  • CGON shares jumped after positive phase 3 results for cretostimogene in bladder cancer; Phase 3 PIVOT-006 trial evaluated cretostimogene in non-muscle-invasive bladder cancer; treatment reduced the risk of recurrence by 68% versus current therapy in intermediate-risk patients.
  • CYTK said the FDA has approved a sNDA updating the U.S. Prescribing Information for MYQORZO(R) (aficamten) to include data from MAPLE-HCM, the Phase 3 trial comparing MYQORZO and the standard-of-care beta-blocker metoprolol, each as monotherapy, in adults with symptomatic oHCM.
  • INCY said it has decided not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, the company's selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenance therapy in patients with ovarian cancer, which had been expected to begin in Q4.
  • JNJ is acquiring privately held Ollin Bio for $2.2 billion upfront. Ollin is developing treatments for diseases that caused age-related vision loss.
  • LLY will acquire privately held Calytrix, and Calytrix shareholders could receive up to $1.5B in cash.
  • LXEO shares jumped following positive interim trial results for a treatment for a rare genetic heart disease; said interim data from an ongoing Phase I/II clinical trial of LX2020, a treatment for PKP2 arrhythmogenic cardiomyopathy, strengthened its confidence in the drug's potential.
  • SMMT shares fall after saying the FDA declined approval of their lung cancer drug ivonescimab saying the drug's benefit in delaying disease progression does not support a favorable benefit-risk profile without a statistically significant improvement in overall survival. Ivonescimab plus chemotherapy cut the risk of disease progression or death by 48% vs. chemotherapy alone in a late-stage trial.
  • VKTX highlights clinical data from VK2735 obesity program at Obesity Week 2026; VK2735 treatment led to improvement in multiple cardiometabolic markers; said 74% of participants receiving VK2735 improved BMI category after 13 weeks.
  • ZYME announced that its Board of Directors has authorized a second 2026 share repurchase program under which the company may repurchase up to $200M of its outstanding common stock.

Healthcare Services & MedTech movers:

  • HSIC reduces FY2026 non-Gaap diluted eps guidance to $5.42-$5.48 from $5.50-$5.56 vs. consensus of $5.54 and sees FY sales growth outlook 4.5-5.5%; guidance is for current continuing operations and does not include impact of restructuring expenses.
  • MDT agreed to acquire Contego Medical for $380M, a private med device company focused on carotid artery disease and peripheral thrombectomy. Medtronic expects to complete the transaction in the third quarter of its fiscal year, subject to customary closing conditions.
  • MMED shares edged higher early after saying the FDA has cleared MiniMed Fit, the company's first tubeless insulin pump. Its launch is expected to begin with a phased rollout in the US in spring 2027, following an early customer experience phase. The pump is cleared for people with Type 1 and Type 2 diabetes ages 7 and older

Industrials & Materials

  • Transport sector: Friday's nationwide ground stop continued to impact airlines operations through the weekend. Using data from FlightAware, UBS calculated that the average cancelation rates across the top 6 US airlines was 32% on Nov 13, 30% on Nov 14, and ~10% on Nov 15 (as of 7pm ET). Delays % averaged 25 30% across each of the past 3 days. JBLU and AAL had the highest cancelation rates while LUV had the lowest cancelations % across the top 6. As of Sun evening, it appears that operations are set to improve meaningfully come Monday with cancel rates moderating to flat to LSD% across the major airlines. Friday's nationwide ground stop lasted for over 4 hours.
  • Defense sector: LHX shares fell after officials blamed a nationwide flight shutdown on the FAA contractor's router installation. Transportation Secretary Sean Duffy said Friday that LHX was conducting routine maintenance to switch telecommunication lines from old copper wire to fiber at least one remote location. Duffy said investigators had not determined whether installer error or faulty equipment caused the disruption, which affected communications at 17 of 22 FAA en route centers. Drone maker USAR shares fell after William Blair downgraded to MP from OP saying recent feedstock shortages add to its list of near-term challenges/ pushing out USA Rare Earth's sales and margin estimates well into 2028.
  • Aerospace sector: A Vulcan rocket owned by United Launch Alliance, the joint venture of BA and LMT, failed on Sunday shortly after liftoff from Florida, destroying its payload of 40 satellites from Amazon's Leo internet network in the launch company's first mission failure. The rocket failed roughly 10 minutes after liftoff from the Cape Canaveral Space Force Station in Florida, and the cause was not immediately clear. YSS was upgraded from Hold to Buy at Canaccord after earnings results and PT lowered from $13.50 to $9 noting Q3 revenue of $84.2M declined 7.3% Y/Y, and adjusted EBITDA loss was $27.6M; results missed Canaccord's estimates by approximately 18% and 105%.

Materials, Metals & Mining

  • Chemical sector: Keybanc said they are is reassessing their contrarian position on Crop chemicals and taking a step back, reducing its estimates, and becoming more Selective with its picks. The firm downgraded FMC to Sector Weight as the risk from a prolonged downturn can materially affect its turnaround plan while believes that CTVA is better positioned to weather a delayed recovery. The firm notes underlying demand and pricing for Crop chemicals appear weaker than expected, especially in South America.
  • Paper & Forest sector: CLW announced new leadership appointments; announces Q3 price increase: $50/ton cup, $60/ton folding carton; reaffirms Q4 2026 guidance of $10M-$20M adj ebitda; says Cypress Bend mill outage completed; mill resuming normal operations; expects 2027 capital expenditures within $70 mln-$80 mln maintenance plus $10 mln-$20 mln for projects. Truist noted in the boxboard sector (GPK, SW, GEF), according to Fastmarkets RISI's (RISI) Paper Packaging Monitor, SBS operating rates and pricing could decline over the next few years, barring any future additional capacity closures.
  • Metals & Mining sector: NUE was upgraded to Buy from Neutral at UBS and raise tgt to $307 from $256 saying despite higher hot-rolled coil prices since June, Nucor shares are broadly flat. The firm sees upside to 2027 EBITDA estimates for the company amid expanding backlogs.

Technology

  • NVDA shares stay weak as investors digested a report that supporters of Jensen Huang are lobbying for his return to the AI chip giant following his abrupt resignation last week. Huang has discussed returning as CEO with confidants, the Financial Times reported Sunday. Huang resigned last week following reports of affairs, including one with a woman who was reportedly suspected of being a Chinese spy.
  • New Commerce Department rules impose additional licensing requirements affecting advanced-processor transfers to data centers in several countries. The same market roundup reported that Baidu’s AI businesses helped offset weakness in online advertising.
  • AI sector focused on Anthropic (ANT) IPO this week. Anthropic is expected to price its initial public offering (IPO) on Wednesday, Nov. 18. It will begin trading on Thursday, Nov. 19. In an amended S-1 filing, Anthropic said it expects to sell 825 million shares priced between $70 and $78. That would give the company a market valuation of between $1.3 trillion and $1.45 trillion. Anthropic was initially projected to hit the market with a valuation as high as $2 trillion, but recent market turmoil in the AI sector has knocked that down significantly.
  • AI Infrastructure sector: Server makers' shares continue to slide with shares of DELL, SMCI, HPE lower again, adding to last week’s losses following a leadership crisis at AI chip giant NVDA has exacerbated AI worries amid concerns over spending. DELL has dropped over 40% from Sept peak, HPE down ~34% from Oct record high, SMCI has slumped 75%+ from March 2024 peak.
  • HPC Data Center stocks remain weak with more notable declines for IREN, HUT, CIFR, WULF, CLSK and others. IREN is now -57% YTD and -32% on the month adding to weakness in the data center/HPC compute sector after the Midterm elections added to already negative sentiment in the space on moratorium build concerns - especially in Texas. Other names extending declines include CIFR -56% YTD and -12.5% MTD, and CLSK (-39% YTD and -19% this month)
  • Data Centers: Blackstone Digital Infrastructure Trust (BXDC) said it agreed to acquire a 75.1% controlling interest in a $5B joint venture with Amazon Data Services (AMZN), comprising 13 newly built data centers in Indiana and Mississippi with 647 MW of capacity. The transaction values the properties at a 7.0% initial cap rate and will be funded with $1.9B of Blackstone equity and approximately $2.5B of non-recourse mortgage debt, with Amazon retaining a 24.9% stake. Amazon will lease 100% of the properties under 12-year initial triple-net leases, with 2.75% annual rent escalators and parent guarantees.

Not offered or endorsed by Regal Securities

Street Recommendations

Monday, November 16, 2026

B. RILEY

  • NCMI B. Riley upgraded National CineMedia to Buy from Neutral with a price target of $3, up from $2.50.

BARCLAYS

  • ABBV Barclays raised the firm's price target on AbbVie to $335 from $325 and keeps an Overweight rating on the shares post the Q3 report. In the current environment, AbbVie's "derisked earnings profile is just the type of company that generalists want to own," the analyst tells investors in a research note.
  • AMGN Barclays analyst Emily Field raised the firm's price target on Amgen to $430 from $400 and keeps an Equal Weight rating on the shares post the Q3 report. With strong performance for most of Amgen's growth drivers, the shares shrugged off the disappointing pelacarsen data, the analyst tells investors in a research note.
  • CBRE Barclays analyst Brendan Lynch lowered the firm's price target on CBRE Group to $161 from $183 and keeps an Overweight rating on the shares. The firm reduced estimates for the commercial real estate servicers to reflect capital markets activity in Q4 and in 2027 as a result of higher interest rates. However, it believes "growth in resilient businesses and leasing activity remains attractive."
  • LLY Barclays analyst Emily Field raised the firm's price target on Eli Lilly to $1,550 from $1,400 and keeps an Overweight rating on the shares post the Q3 report. While one-time benefits helped the quarter, Bridge uptake, international demand and share gains reinforce Eli Lilly's underlying growth, the analyst tells investors in a research note. Barclays continues to see room for growth for the company.
  • JLL Barclays raised the firm's price target on JLL to $404 from $401 and keeps an Equal Weight rating on the shares. The firm reduced estimates for the commercial real estate servicers to reflect capital markets activity in Q4 and in 2027 as a result of higher interest rates. However, it believes "growth in resilient businesses and leasing activity remains attractive."
  • SMMT Barclays analyst Etzer Darout lowered the firm's price target on Summit Therapeutics to $18 from $20 and keeps an Equal Weight rating on the shares. The firm says the complete response letter for ivonescimab has limited direct valuation impact on the shares. However, the CRL potentially has more meaningful implications for Summit's lung cancer program given what appears to be a higher FDA efficacy bar, the analyst tells investors in a research note.

BERNSTEIN

  • MAR Bernstein analyst Richard Clarke raised the firm's price target on Marriott to $479 from $445 and keeps an Outperform rating on the shares. The U.S. is seen as the hottest market, with Marriott calling out about 6% organic growth even post-World Cup. All expect trends to remain resilient, with strong demand across customer segments outpacing slow supply growth, the firm says. Construction is improving, but even with strong RevPAR, new builds are not rapidly returning, adds Bernstein.
  • HLT Bernstein raised the firm's price target on Hilton to $380 from $320 and keeps a Market Perform rating on the shares. The U.S. is seen as the hottest market, and all expect trends to remain resilient, with strong demand across customer segments outpacing slow supply growth, the firm says. Construction is improving, but even with strong RevPAR, new builds are not rapidly returning, adds Bernstein.
  • H Bernstein raised the firm's price target on Hyatt to $231 from $202 and keeps an Outperform rating on the shares. The U.S. is seen as the hottest market, and all expect trends to remain resilient, with strong demand across customer segments outpacing slow supply growth, the firm says. Construction is improving, but even with strong RevPAR, new builds are not rapidly returning, adds Bernstein.
  • IHG Bernstein raised the firm's price target on InterContinental to $177 from $154 and keeps a Market Perform rating on the shares. The U.S. is seen as the hottest market, and all expect trends to remain resilient, with strong demand across customer segments outpacing slow supply growth, the firm says. Construction is improving, but even with strong RevPAR, new builds are not rapidly returning, adds Bernstein.

BOFA

  • AWK BofA analyst Ross Fowler raised the firm's price target on American Water to $157 from $142 and keeps a Neutral rating on the shares. American Water has received four of eight required state approvals for its pending merger, with settlements filed in the remaining four states and a New Jersey vote the next catalyst, the analyst tells investors.

BTIG

  • GKOS BTIG analyst Ryan Zimmerman raised the firm's price target on Glaukos to $252 from $234 and keeps a Buy rating on the shares. The firm believes that the company's FY27 revenue guidance of $1B is achievable but requires Epioxa to continue on its current trajectory, iDose to hold its footing, and outside U.S to remain a steady contributor, the analyst tells investors in a research note.

CANACCORD

  • BLTE Canaccord analyst Whitney Ijem raised the firm's price target on Belite Bio to $314 from $303 and keeps a Buy rating on the shares. The firm updated its model following Q3 results with the new update was that the FDA told the co that it will not hold an advisory committee meeting for the tinlarebant NDA. Management noted that the mid-cycle review went smoothly and a late-cycle review date is set. Taken together, they think this bodes well heading into the PDUFA.
  • ENVX Canaccord lowered the firm's price target on Enovix to $2.50 from $10 and keeps a Buy rating on the shares. The firm updated its model as the company announced they are pausing its smartphone ambitions, channeling its all-silicon cell into smart eyewear, and doubling down on drone and defense technology.
  • LUNR Canaccord lowered the firm's price target on Intuitive Machines to $38 from $39 and keeps a Buy rating on the shares. The firm updated its model following Q3 results as the company showcased attractive yearly growth and margin improvement, in part due to Lanteris business.
  • NKTR Canaccord analyst Edward Nash lowered the firm's price target on Nektar to $149 from $153 and keeps a Buy rating on the shares. The firm updated its model following Q3 results which were driven by lower than expected R&D expenditure. The company also announced they will be pursuing nonsegmental vitiligo as an additional indication of study for rezpeg.

CANTOR FITZGERALD

  • LEU Cantor Fitzgerald initiated coverage of Centrus Energy with an Overweight rating and $130 price target. The firm says Centrus is the only publicly traded, U.S.-owned uranium enricher and the only domestic producer of high-assay low-enriched uranium. Cantor sees U.S. electricity demand "inflecting" after a decade of stagnation, driven by data centers and coal retirements. In addition, the Russian uranium import ban removes roughly 20% of U.S. enrichment supply by 2028, the analyst tells investors in a research note.

CITI

  • SMMT Citi analyst Yigal Nochomovitz lowered the firm's price target on Summit Therapeutics to $42 from $43 and keeps a Buy rating on the shares. The firm cites the complete response letter for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer for the target cut.
  • DELL Citi lowered the firm's price target on Dell Technologies to $550 from $600 and keeps a Buy rating on the shares. The firm adjusted targets in the hardware and storage group as part of a Q3 earnings preview. Hardware enterprise infrastructure names should post strong results given the broader refresh cycle, the analyst tells investors in a research note.
  • HPE Citi lowered the firm's price target on HPE to $80 from $92 and keeps a Buy rating on the shares. The firm adjusted targets in the hardware and storage group as part of a Q3 earnings preview. Hardware enterprise infrastructure names should post strong results given the broader refresh cycle, the analyst tells investors in a research note.
  • BOX Citi raised the firm's price target on Box to $55 from $40 and keeps a Buy rating on the shares. The firm says Box continues to be its top pick in application software post the Q3 reports. The company's growth outlook is accelerating with its "infrastructure-like offering," expanded focus in regulated industries, and agentic security value proposition, the analyst tells investors in a research note.
  • RIVN Citi lowered the firm's price target on Rivian to $14.50 from $18 and keeps a Neutral rating on the shares. The company's nine-month revenue was up 27% to $5.2B and R2 production is accelerating, the analyst tells investors in a research note. Citi cites reduced valuation levels for the group for the target cut.
  • SPCX Citi raised the firm's price target on SpaceX to $280 from $240 and keeps a Buy rating on the shares following the Starship Flight 15. The firm says the successful catch of Starship using Mechazilla's arms was one of the milestones it flagged when outlining the stock's multi-year path toward $900. Citi left this weekend's flight with greater conviction in SpaceX's super intelligence segment outlook.

EVERCORE ISI

  • NTAP Evercore ISI analyst Amit Daryanani added NetApp to the firm's "Tactical Outperform" list ahead of the company's earnings release due on December 1. The firm expects "a solid beat," with the bigger question being how much NetApp raises the second half outlook and whether operating leverage can continue to offset pressure on product gross margins, says the analyst, who maintains an Outperform rating and $300 price target on the shares.

GOLDMAN SACHS

  • YETI Goldman Sachs downgraded Yeti to Neutral from Buy with a price target of $41, down from $57, post the Q3 report. The firm now has less conviction in Yeti's potential for outperformance, saying domestic consumer demand has softened and cost pressures continue to build into 2027. Goldman acknowledges its Buy call was wrong, and steps to the sidelines citing a more balanced risk/reward at current share levels. According to TipRanks, Goldman has a 3-star analyst on Yeti. [View TipRanks Star Ranking]:[https://www.tipranks.com/experts/analysts/brooke-roach]

JEFFERIES

  • SPCE Jefferies analyst Sheila Kahyaoglu lowered the firm's price target on Virgin Galactic to $4 from $5 and keeps a Buy rating on the shares. The Apeiron commercial service has been delayed to early Q2 of 2027 from February, the analyst tells investors in a research note. Jefferies cites the later ramp for the target cut.
  • ULTA Jefferies raised the firm's price target on Ulta Beauty to $766 from $730 and keeps a Buy rating on the shares. Improved investor sentiment, alongside a constructive beauty backdrop, sets up "a solid Q3," the analyst tells investors in a preview.

JPMORGAN

  • BAP JPMorgan analyst Yuri Fernandes raised the firm's price target on Credicorp to $490 from $482 and keeps an Overweight rating on the shares. Despite the increased El Nino-related risks in the near-term, Credicorp combines a favorable macroeconomic backdrop in Peru with a company-specific growth story, as it expands faster in businesses with higher return on equity, such as Yape, the analyst tells investors in a research note.
  • OVV JPMorgan raised the firm's price target on Ovintiv to $84 from $74 and keeps an Overweight rating on the shares post the Q3 report. The stock has rallied on successful portfolio management moves, strong results in the field, and a highly successful inventory renewal strategy, the analyst tells investors in a research note. JPMorgan likes the stock's near-term risk/reward citing the expected completion of repairs at the Albright midstream facility ahead of schedule.
  • QTWO JPMorgan raised the firm's price target on Q2 Holdings to $82 from $76 and keeps an Overweight rating on the shares. The firm saysQ2's next growth catalyst appears in subscription annual recurring revenue well before it reaches reported revenue. It sees the company's Q4 bookings setting the company up well for fiscal 2028.
  • HAS JPMorgan raised the firm's price target on Hasbro to $145 from $111 and keeps an Overweight rating on the shares. The firm updated the company's model after meeting with management. Wizards outperformance continues while Hasbro is seeing growth in consumer products, the analyst tells investors in a research note.

KEYBANC

  • FMC KeyBanc downgraded FMC to Sector Weight from Overweight without a price target. Underlying demand and pricing for crop chemicals appear weaker than expected, especially in South America, the analyst tells investors in a research note. The firm says crop prices have largely reversed their summer gains. It believes risk from a prolonged downturn can "materially affect" FMC's turnaround plan.
  • CTRE KeyBanc analyst Austin Wurschmidt lowered the firm's price target on CareTrust REIT to $43 from $46 to reflect a lower target multiple amid higher long-term rates, while keeping an Overweight rating on the shares. The firm is increasing its 2026 and 2027 nFFO estimates by 1% following Q3 earnings and last week's equity issuance.
  • CTVA KeyBanc lowered the firm's price target on Corteva to $14 from $17 and keeps an Overweight rating on the shares. The firm believes the company is facing an earning reset, yet it thinks the shares are attractive at roughly six-times EBITDA, which suggests it is a fully commoditized company or that the market is likely to continue to deteriorate, both views KeyBanc doesn't share.

MACQUARIE

  • BILI Macquarie downgraded Bilibili to Neutral from Outperform with a price target of $13.90, down from $24.20. The firm cut the company's advertising revenue estimates to reflect potential ad budget shifts. It cites greater advertising earnings risk from short-drama competition for the downgrade of Bilibili.

MIZUHO

  • NVDA Mizuho analyst Vijay Rakesh lowered the firm's price target on Nvidia to $220 from $250 and keeps an Outperform rating on the shares. The firm believes the 32% selloff from the stock's October peak reflects lost Jensen Huang premium. While we Nvidia faces challenges and risks, investors will refocus on the company's fundamentals and execution, the analyst tells investors in a research note. Mizuho believes Nvidia is "set up attractively with a strong roadmap."
  • NPCE Mizuho analyst Anthony Petrone lowered the firm's price target on NeuroPace to $12 from $22 and keeps an Outperform rating on the shares following the Q3 report. The company cut its full-year revenue outlook by 9% at the midpoint with disruption at key accounts, a sales force restructuring, and exit from the distribution business called out as headwinds impacting the business, the analyst tells investors in a research note. The firm reduced estimates post the earnings print.

MORGAN STANLEY

  • BZ Morgan Stanley lowered the firm's price target on Kanzhun to $18 from $24 and keeps an Overweight rating on the shares. The firm, which forecast revenue growth to reach 12% year-over-year in Q3, expects Q3 revenue and billings to meet guidance. The firm lowered its earnings estimates 8% for 2026, 9% for 2027 and 14% for 2028 to reflect lower revenue forecasts in view of weaker hiring demand, but thinks the 25% share price correction has "fully priced in market concern."

NEEDHAM

  • EFX Needham raised the firm's price target on Equifax to $220 from $210 and keeps a Buy rating on the shares after meeting with its management team to discuss workforce solutions and mortgage policy. Coming off the event, the firm is "bullish on the stock" as the company is well-positioned to meet or exceed its long-term financial targets, the analyst tells investors in a research note. Needham adds that the stock's earnings multiple of 18 times is a discount to historical levels.

NORTHCOAST

  • COST Northcoast downgraded Costco to Neutral from Buy without a price target. The firm cites valuation for the downgrade with the shares above its prior price target.

PIPER SANDLER

  • MIST Piper Sandler lowered the firm's price target on Milestone Pharmaceuticals to $3 from $7 on lower CARDAMYST sales, while keeping an Overweight rating on the shares. The firm notes Milestone is conducting the Phase III ReVeRA-301 trial of CARDAMYST in AFibRVR with top-line data expected in the second half of 2028. Milestone plans to partner etripamil outside the U.S. and China for PSVT and AFib-RVR.
  • HUT Piper Sandler analyst Patrick Moley lowered the firm's price target on Hut 8 to $115 from $123 and keeps an Overweight rating on the shares. The firm sees AI/HPC Data Center Developers -- aka BTC Miners -- disproportionately hurt by AI revaluation. Of the 6 AI and AI-adjacent baskets Piper examined, the BTC miners underperformed all but Optics since 9/1/26, and trailed memory, another highly volatile sector, by nearly 10pp. A punishing beta relative to the rest of AI is not new for the group, but when it shows up it can create strong buying opportunities, adds Piper.
  • MARA Piper Sandler lowered the firm's price target on Mara Holdings to $10 from $11 and keeps an Overweight rating on the shares. The firm sees AI/HPC Data Center Developers -- aka BTC Miners -- disproportionately hurt by AI revaluation. Of the 6 AI and AI-adjacent baskets Piper examined, the BTC miners underperformed all but Optics since 9/1/26, and trailed memory, another highly volatile sector, by nearly 10pp. A punishing beta relative to the rest of AI is not new for the group, but when it shows up it can create strong buying opportunities, adds Piper.
  • RIOT Piper Sandler raised the firm's price target on Riot Platforms to $25 from $19 and keeps an Overweight rating on the shares. The firm sees AI/HPC Data Center Developers -- aka BTC Miners -- disproportionately hurt by AI revaluation. Of the 6 AI and AI-adjacent baskets Piper examined, the BTC miners underperformed all but Optics since 9/1/26, and trailed memory, another highly volatile sector, by nearly 10pp. A punishing beta relative to the rest of AI is not new for the group, but when it shows up it can create strong buying opportunities, adds Piper.

RBC CAPITAL

  • CNNE RBC Capital analyst Kenneth Lee downgraded Cannae Holdings to Sector Perform from Outperform with a price target of $18, up from $17. The firm sees limited upside potential to the shares based on its sum-of-the-parts valuation. Portfolio monetization's and share repurchases could be an upside risk for Cannae, but RBC awaits more line of sight, the analyst tells investors in a research note. RBC cites valuation for the downgrade.
  • HUM RBC Capital upgraded Humana to Outperform from Sector Perform with a price target of $563, up from $415. The company's "impressive" Stars turnaround, alongside disciplined medical cost management amid 23% individual MA membership growth this year, "demonstrates significant earnings potential," says the analyst, who sees "a clear pathway" to $38-$42 in EPS by 2028.

ROSENBLATT

  • DLB Rosenblatt lowered the firm's price target on Dolby to $80 from $85 and keeps a Buy rating on the shares ahead of the earnings report on November 17. The firm expects a slight quarterly beat with conservative guidance. It cites the market environment for the target cut.

STEPHENS

  • KPLT As previously reported, Stephens upgraded Katapult to Overweight from Equal Weight with a price target of $15, up from $6.50, after the company reported its inaugural quarter since its merger closed in August. The firm, which appreciates the size, scale, diversification, and revenue and expense synergies from the merger, sees a steady path over time for earnings growth as Katapult optimizes its balance sheet, the analyst tells investors.

STIFEL

  • ONDS Stifel analyst Jonathan Siegmann lowered the firm's price target on Ondas to $15 from $18 and keeps a Buy rating on the shares.
  • SITE Stifel raised the firm's price target on SiteOne Landscape to $108 from $102 and keeps a Hold rating on the shares.
  • TRGP Stifel raised the firm's price target on Targa Resources to $340 from $335 and keeps a Buy rating on the shares.
  • ZBH Stifel analyst Rick Wise raised the firm's price target on Zimmer Biomet to $140 from $125 and keeps a Buy rating on the shares.

TD COWEN

  • SPXC TD Cowen upgraded SPX Technologies to Buy from Hold with a price target of $200, down from $225. The "froth" in the shares has been replaced with AI fear while SPX's margins have been reset to reflect higher costs, the analyst tells investors in a research note. TD sees current share levels as a "more palatable entry for the same attractive growth profile." SPX's revenue ramp "looks real," and incremental data center capacity above current plans may need to be evaluated, contends the firm. According to TipRanks, TD has a 5-star analyst on SPX Technologies. [View TipRanks Star Ranking]:[https://www.tipranks.com/experts/analysts/joseph-c-giordano]

TRUIST

  • ECPG Truist downgraded Encore Capital to Hold from Buy with a price target of $115, down from $122. Shares have doubled this year and the key driver of earnings upside has been "changes in recoveries," which represent portfolio outperformance along with mark-to-market adjustments, the analyst tells investors. The business model is operating well, but with no material inflection, the persistency of elevated portfolio gains is difficult to judge, the analyst added.

UBS

  • NUE UBS upgraded Nucor to Buy from Neutral with a price target of $307, up from $256. Despite higher hot-rolled coil prices since June, Nucor shares are broadly flat, the analyst tells investors in a research note. The firm sees upside to 2027 EBITDA estimates for the company amid expanding backlogs. UBS cites Nucor's free cash flow and buyback potential for the upgrade.
  • OFG UBS initiated coverage of OFG Bancorp with a Sell rating and $50 price target. The firm sees intensifying deposit competition and slowing consumer growth weighing on the bank's earnings. OFG has been among the best performing stocks in the sector in 2026, but "the path gets tougher from here," the analyst tells investors in a research note.
  • FBP UBS analyst Timur Braziler initiated coverage of First BanCorp with a Neutral rating and $27 price target. The bank's net interest margin and and credit trends are likely soften through fiscal 2028, the analyst tells investors in a research note. UBS views First BanCorp as one of the best of the Puerto Rico banks, but says this is reflected in the stock's "premium" multiple.
  • VIV UBS last night upgraded Telefonica Brasil to Neutral from Sell with a price target of R$38, up from R$31.50. The firm says its Sell thesis has largely played out with stock down 18% in the last nine months. Competitive pressure has had a much smaller impact on Telefonica Brasil's growth than fared and now appears to be stabilizing, the analyst tells investors in a research note.
  • STLD UBS lowered the firm's price target on Steel Dynamics to $257 from $276 and keeps a Neutral rating on the shares. Higher HRC prices lift steel earnings estimates, but weaker aluminum and fabrication results and expected price normalization drive the lower price target, the analyst tells investors in a research note.
  • SMTC UBS lowered the firm's price target on Semtech to $200 from $230 and keeps a Buy rating on the shares. Semtech is positioned for continued revenue and EPS growth, driven by accelerating data center AI deployments and LoRa opportunities, with rising data center and LoRa mix expected to support gross margins, the analyst tells investors in a research note.
  • DLTR UBS raised the firm's price target on Dollar Tree to $165 from $150 and keeps a Buy rating on the shares. Dollar Tree's Q3 results should demonstrate improving underlying performance and returning customer traffic, despite tariff-related reinvestment and higher fuel costs creating headline volatility, the analyst tells investors in a research note.
  • NVDA UBS lowered the firm's price target on Nvidia to $240 from $300 and keeps a Buy rating on the shares. Nvidia is expected to beat near-term revenue estimates and maintain its product roadmap, but potential export restrictions and data center delays prompt a 10% cut to 2028 revenue and EPS estimates despite continued strong demand, the analyst tells investors in a research note.
  • XRAY UBS analyst Kevin Caliendo lowered the firm's price target on Dentsply Sirona to $13 from $17 and keeps a Buy rating on the shares. The disappointing Q3 results increase uncertainty around its growth and earnings outlook, with turnaround progress likely to take time and limited 2027 visibility keeping shares range-bound near term, the analyst tells investors in a research note.

WELLS FARGO

  • SGHC Wells Fargo analyst Zachary Silverberg initiated coverage of Super Group with an Equal Weight rating and $13 price target. The company has operating leverage, free cash flow, and expansion opportunities in Sub-Saharan Africa but its international exposure adds tax regime risk, the analyst tells investors in a research note. Wells sees limited multiple expansion for Super Group shares in the current environment.
  • CCOI Wells Fargo downgraded Cogent to Underweight from Equal Weight with a price target of $4, down from $14. The company's Q3 results missed estimates, the quarterly SEC filing added a going-concern warning, and the dividend was suspended, the analyst tells investors in a research note. Wells says Cogent management also gave no terms or timeline on its $700M June 2027 maturities. The company is now a levered call option on 2027 refinancing, contends the firm. It believes Cogent's fundamental business continues to weaken. Wells cut estimates and downgraded he shares to Underweight.
  • HAS Wells Fargo raised the firm's price target on Hasbro to $115 from $100 and keeps an Equal Weight rating on the shares. The firm attended MagicCon Atlanta, including a meeting with CFO Gina Goetter and MTG leadership. Engagement looked strong as ever, Reality Fracture/Star Trek seem on track, and the company seemed confident in further momentum into 2027 plus additional growth levers beyond, adds Wells.
  • EW Wells Fargo raised the firm's price target on Edwards Lifesciences to $121 from $113 and keeps an Overweight rating on the shares ahead of investor meeting. Wells expects the company to reiterate its Q4 2026 guidance and provide 2027 underlying revenue guidance of 8%-10% and EPS guidance of $3.30-$3.45.
  • MMM Wells Fargo analyst Stephen Tusa raised the firm's price target on 3M to $205 from $195 and keeps an Equal Weight rating on the shares. The 3M PFAS settlement removes uncertainty, another step in the transformation under current management, the firm says. The cash burden remains, along with liability tails, and recent outperformance leaves limited upside in the stock, adds Wells.
  • SPB Wells Fargo assumed coverage of Spectrum Brands with an Equal Weight rating with a price target of $87, up from $85. Valuation may have room, but organic sales delivery is historically inconsistent with materially tougher comparisons ahead, and the firm sees little flex in the model into FY27.

WILLIAM BLAIR

  • BILL William Blair analyst Andrew Jeffrey upgraded Bill to Outperform from Market Perform without a price target. The firm likes Bill for longer-term investors seeking exposure to a "leading pure-play B2B provider." The company is positioned for improving monetization and "more robust-than-expected" margin expansion, the analyst tells investors in a research note. Blair cites growing confidence in Bill's ideal customer profile strategy for the upgrade. The Street underestimates the potential to gain additional traction, contends the firm.
  • STIM William Blair analyst Steven Lichtman initiated coverage of Neuronetics with an Outperform rating. Under new senior leadership, Neuronetics has initiated several new strategies that have delivered positive early results, the analyst tells investors in a research note. The firm says the company's core NeuroStar transcranial magnetic stimulation system is now being offered through more flexible purchasing models, opening up new customer segments. Blair believes the shares do not reflect Neuronetics' underlying improvements or new drivers ahead.

Rating abbreviations…

***OP = Outperform

***SP = Sector Perform

***UP = Underperform

***OW = Overweight

***EW = Equal-weight

***UW = Underweight

 

 

 

 

***Report powered by thefly.com***

What’s on Tap Weekly Calendar

 

Monday November 16th

Economic Calendar: 

  • 8:30 AM ET NY Empire Manufacturing for November

Earnings Calendar:

  • Earnings Before the Open: ARMK BEKE BIDU BLDP BXDC DTST GAME HTHT IQ PERI POET TSN VENU XPEV XTNT XXII
  • Earnings After the Close: ACM AYTU BAER BRFH DARE DUOT FTLF INFQ MNTK OMER PAGS PARA POWL RCAT SHAZ STEM TMS TRAK WRAP XP YALA

Other Key Events:

  • Piper Sandler Financial Services Conference, 11/16-11/18, in Miami, FL
  • RBC Capital Markets Global Industrials Conference 11/16-11/17, in New York
  • Roth Capital 13th Annual Solar & Storage Symposium at RE +, 11/16-11/18, Las Vegas
  • Supercomputing 2026, 11/15-11/20, in New Orleans

Tuesday November 17th

Economic Calendar: 

  • 7:45 AM ET ICSC Weekly Retail Sales
  • 8:30 AM ET                   Retail Sales M/M for October
  • 8:30 AM ET                   Retail Sales – Less Autos M/M for October
  • 8:30 AM ET                   Import Prices M/M for October
  • 8:30 AM ET                   Export Prices M/M for October
  • 8:55 AM ET                   Johnson/Redbook Weekly Sales
  • 9:15 AM ET                   Industrial Production M/M for October
  • 9:15 AM ET                   Capacity utilization for October
  • 10:00 AM ET                 Business Inventory M/M for September
  • 10:00 AM ET NAHB Housing Market Index for November
  • 4:30 PM ET API Weekly Inventory Data

Earnings Calendar:

  • Earnings Before the Open: AS DIS ENR ESLT FUBO GFF HD HUYA JD KLAR LUXE MNSO ONEW OPRA SMWB SR TME VIK WB
  • Earnings After the Close: DLB GBDC GLAD IIIV IRIX LZB NVDA SQM WAST ZTO

Other Key Events:

  • Citizens Financial Services Conference, 11/17, in New York
  • Deutsche Bank Residential REIT summit (virtual), 11/17
  • Deutsche Bank 5th Annual Global Space Summit, 11/17-11/18, in New York
  • Jefferies 5th Miami Consumer Conference, 11/17-11/18, in Miami, FL
  • Piper Sandler Financial Services Conference, 11/16-11/18, in Miami, FL
  • RBC Capital Markets Global Industrials Conference 11/16-11/17, in New York
  • RBC Capital 2026 Global TIMT Conference, 11/17-11/18, in New York
  • Rosenblatt Silicon Valley field trip, 11/17-11/18
  • Roth Capital 13th Annual Solar & Storage Symposium at RE +, 11/16-11/18, Las Vegas
  • Roth Capital 15th Annual Technology Conference, 11/17-11/18, in New York
  • Supercomputing 2026, 11/15-11/20, in New Orleans
  • TD Cowen 2026 Financials & Fintech Conference, 11/17-11/18, in New York

Wednesday November 18th

Economic Calendar: 

  • 7:00 AM ET MBA Mortgage Applications Data
  • 8:30 AM ET                   Housing Starts M/M for October
  • 8:30 AM ET                   Building Permits M/M for October
  • 10:00 AM ET                 Pending Home Sales M/M for October
  • 10:30 AM ET                 Weekly EIA Inventory Data
  • 1:00 PM ET US Treasury to sell $13B in 20-year notes
  • 4:00 PM ET                    Net Long-term TIC Flows for September

Earnings Calendar:

  • Earnings Before the Open: BLSH BRBR CSHR GLBE GLNG JJSF JMIA KRNT LOW PONY PRE TCEHY TGT TJX ZIM ZKH
  • Earnings After the Close: CPA HP JOYY KLIC NJR P PANW PCYO RRGB SBLK UGI UTI WWD

Other Key Events:

  • Deutsche Bank 5th Annual Global Space Summit, 11/17-11/18, in New York
  • Jefferies 5th Miami Consumer Conference, 11/17-11/18, in Miami, FL
  • Piper Sandler Financial Services Conference, 11/16-11/18, in Miami, FL
  • RBC Capital 2026 Global TIMT Conference, 11/17-11/18, in New York
  • Rosenblatt Silicon Valley field trip, 11/17-11/18
  • Roth Capital 13th Annual Solar & Storage Symposium at RE +, 11/16-11/18, Las Vegas
  • Roth Capital 15th Annual Technology Conference, 11/17-11/18, in New York
  • Supercomputing 2026, 11/15-11/20, in New Orleans
  • TD Cowen 2026 Financials & Fintech Conference, 11/17-11/18, in New York

Thursday November 19th

Economic Calendar: 

  • 8:30 AM ET                   Weekly Jobless Claims
  • 8:30 AM ET                   Continuing Claims
  • 8:30 AM ET                   Philly Fed Business Index for November
  • 10:00 AM ET                 Leading Index M/M for October
  • 10:30 AM ET                 Weekly EIA Natural Gas Inventory Data
  • 11:00 AM ET                 Kansas City Fed Manufacturing for November

Earnings Calendar:

  • Earnings Before the Open: ARBE BABA BBWI DAO EVGN FUTU LQDT MANU MMS NTES RERE ROAD TEN VVV WMG WMT YMM
  • Earnings After the Close: BULL CLIR EARN ESE ESTC GAP GLOB INTU KEYS MATW NGVC POST ROST

Other Key Events:

  • Deutsche Bank Gaming, Lodging, Leisure One on One Conference 11/19-11/20, in Miami, FL
  • Supercomputing 2026, 11/15-11/20, in New Orleans

Friday November 20th

Economic Calendar: 

  • 10:00 AM ET                 University of Michigan Confidence, Nov-Final
  • 10:00 AM ET                 University of Michigan 1-yr and 5-yr inflation expectation, Nov -Final
  • 1:00 PM ET                    Baker Hughes Weekly rig count data

Earnings Calendar:

  • Earnings Before the Open: BJ BKE BSP FRO RLX WRD

Other Key Events:

  • Deutsche Bank Gaming, Lodging, Leisure One on One Conference 11/19-11/20, in Miami, FL
  • Supercomputing 2026, 11/15-11/20, in New Orleans

 

 

.

As a value-added service exclusive to Regal Securities account holders, The Hammerstone Report is available to read daily on the trading platform.

Hammerstone Inc. (the “Report”) provides information and data and does NOT provide any individual investment advice or money management assistance and does NOT attempt to influence the sale or purchase of securities. The Report is intended for informational purposes only and does not claim to be actionable for investment decisions. The information contained in the Report has been obtained from sources deemed to be reliable but is not represented to be complete, and it should not be relied upon as such. The Report does not purport to be a complete analysis of any security, issuer, or industry and is not an offer or a solicitation of an offer to buy or sell any securities. The Report is prepared for general information purposes only and does not consider the specific investment objectives, financial situation, and particular needs of any individual subscriber, person, or entity.

Content is provided for educational and informational purposes only and Regal Securities cannot attest to its accuracy or completeness. No information provided has been endorsed by Regal Securities and does not constitute a recommendation by Regal Securities to buy or sell a particular investment. You are solely responsible for your own investment decisions and Regal Securities makes no investment recommendations and does not provide financial, tax, or legal advice. Regal Securities may provide links to internet sites maintained by third parties. Unless expressly stated otherwise, links in these reports are not sponsored by nor are they the responsibility of Regal Securities. Regal Securities has not verified the content, accuracy, or opinions expressed on any links in these reports and disclaims any warranty or liability for damages associated therewith.

Copyright 2006-2026 Regal Securities, Inc., Member FINRA/SIPC | Important Disclosures

Your privacy is important to us; see our Privacy Policy for details.

Regal Securities, 950 Milwaukee Ave., Ste. 102, Glenview, IL 60025
Website: www.regalsecurities.com | Toll-free: 1-877-488-6534
Representatives are available Monday through Friday from 8:00 a.m. to 5:00 p.m. EST.